title: [Experience with rIL2 in the treatment of metastatic renal carcinoma].
abstract: Eight patients with metastatic renal cell carcinoma, all nephrectomized, were treated with rIL2 continuous i.v. infusion or subcutaneous administering (+/- INF). Six patients alive. Continuous infusion is possible event out of Intensive Care Unity. Adverse effects, sometimes serious, rapidly decrease with suspension. Subcutaneous infusion is more easy and with lower adverse effects. We don't know methodic of which can give more security.
authors.affiliation: Divisione di Medicina Interna, Ospedale Civile Voghera.
authors.forename: P
authors.initials: P
authors.lastname: Cardellini
authors.forename: D
authors.initials: D
authors.lastname: Vicini
authors.forename: M
authors.initials: M
authors.lastname: Ruggieri
authors.forename: G P
authors.initials: GP
authors.lastname: Franceschetti
authors.forename: S
authors.initials: S
authors.lastname: Nicrosini
mesh_terms: D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins
vernacular_title: Esperienze con rIL2 nel trattamento del carcinoma renale metastatizzato.